Vertex Pharmaceuticals
VRTX
689 hedge funds and large institutions have $41B invested in Vertex Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 63 funds opening new positions, 276 increasing their positions, 242 reducing their positions, and 51 closing their positions.
45% more funds holding in top 10
Funds holding in top 10: 11 → 16 (+5)
24% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 51
14% more repeat investments, than reductions
Existing positions increased: 276 | Existing positions reduced: 242
1% more funds holding
Funds holding: 680 → 689 (+9)
4% more capital invested
Capital invested by funds: $39.3B → $41B (+$1.68B)
0.28% less ownership
Funds ownership: 95.02% → 94.74% (-0.28%)
4% less call options, than puts
Call options by funds: $294M | Put options by funds: $306M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$309M |
| 2 |
Renaissance Technologies
New York
|
+$186M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$136M |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$125M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$116M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$298M |
| 2 |
Jennison Associates
New York
|
-$265M |
| 3 |
JP Morgan Chase
New York
|
-$189M |
| 4 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
-$167M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$144M |
VRTX Hedge Fund Activity: Q2 2018 in Review
689 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q2 2018, worth a combined $41B — up 4.3% from $39.3B a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new VRTX positions and 51 closed out — a net gain of 12 holders — while 276 added to existing stakes and 242 trimmed.
The largest buyer was Capital World Investors, adding an estimated $309M. The largest seller was T. Rowe Price Associates, cutting an estimated $298M.
- 689 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q2 2018, up from 680 in Q1 2018.
- Funds reported $41B of Vertex Pharmaceuticals stock for Q2 2018, up 4.3% quarter-over-quarter.
- 63 funds opened new Vertex Pharmaceuticals positions in Q2 2018 and 51 closed out, a net change of +12 holders.
- The largest Vertex Pharmaceuticals buyer in Q2 2018 was Capital World Investors, an estimated $309M added.
- The largest Vertex Pharmaceuticals seller in Q2 2018 was T. Rowe Price Associates, an estimated $298M sold.
Based on aggregated 13F filings for Q2 2018.